Answer
Jun 12, 2025 - 01:20 PM
Etoricoxib, a selective COX-2 inhibitor used for pain and inflammation, has faced regulatory scrutiny due to concerns about cardiovascular risks associated with its use. Some countries have restricted or banned the drug because studies indicated an increased risk of heart attacks and strokes, similar to other drugs in the same class. The decision to restrict or ban etoricoxib often depends on the country's assessment of its risk-benefit profile.
